{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:49:12Z","timestamp":1790754552908,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/ijp.ijp_700_16","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T05:36:52Z","timestamp":1506490612000},"page":"236","source":"Crossref","is-referenced-by-count":26,"title":["The impact of antidepressant treatment on brain-derived neurotrophic factor level: An evidence-based approach through systematic review and meta-analysis"],"prefix":"10.4103","volume":"49","author":[{"given":"Vijayakumar","family":"Arumugam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ViniSusan","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taniya","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SagarMaliakkal","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchandra","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhinadri","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.215729-1","first-page":"593","volume-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-2","unstructured":"Barlow D, Durand V. Abnormal Psychology. 1st ed. Belmont, CA: Wadsworth\/Thomson Learning; 2007. p. 292-5."},{"key":"key-10.4103\/0253-7613.215729-3","first-page":"23","volume-title":"Preliminary longitudinal assessment of quality of life in patients with major depression","author":"Pyne","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"key-10.4103\/0253-7613.215729-4","first-page":"89","volume-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","author":"Biomarkers","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/0253-7613.215729-5","first-page":"1905","volume-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-6","first-page":"539","volume-title":"Are there meaningful biomarkers of treatment response for depression?","author":"Breitenstein","year":"2014","journal-title":"Drug Discov Today"},{"key":"key-10.4103\/0253-7613.215729-7","first-page":"119","volume-title":"Cell biology of BDNF and its relevance to schizophrenia","author":"Lu","year":"2008","journal-title":"Novartis Found Symp"},{"key":"key-10.4103\/0253-7613.215729-8","first-page":"450","volume-title":"A BDNF autocrine loop in adult sensory neurons prevents cell death","author":"Acheson","year":"1995","journal-title":"Nature"},{"key":"key-10.4103\/0253-7613.215729-9","first-page":"1353","volume-title":"Brain-derived neurotrophic factor and antidepressant action: Another piece of evidence from pharmacogenetics","author":"Tsai","year":"2008","journal-title":"Future Med"},{"key":"key-10.4103\/0253-7613.215729-10","first-page":"214","volume-title":"Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population","author":"Xu","year":"2012","journal-title":"Psychiatr Genet"},{"key":"key-10.4103\/0253-7613.215729-11","first-page":"146","volume-title":"BDNF val66Met genotype and 6-month remission rates in late-life depression","author":"Taylor","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"key-10.4103\/0253-7613.215729-12","first-page":"430","volume-title":"Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder","author":"Chi","year":"2010","journal-title":"J Affect Disord"},{"key":"key-10.4103\/0253-7613.215729-13","first-page":"71","volume-title":"Association of brain-derived neurotrophic factor genetic val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients","author":"Zou","year":"2010","journal-title":"Neuropsychobiology"},{"key":"key-10.4103\/0253-7613.215729-14","first-page":"155","volume-title":"Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD)","author":"Katsuki","year":"2012","journal-title":"CNS Spectr"},{"key":"key-10.4103\/0253-7613.215729-15","first-page":"1022","volume-title":"The brain-derived neurotrophic factor (BDNF) polymorphism val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients","author":"Yoshimura","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-16","first-page":"33","volume-title":"No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin","author":"Illi","year":"2013","journal-title":"Psychiatr Genet"},{"key":"key-10.4103\/0253-7613.215729-17","first-page":"1","volume-title":"Association study of a brain-derived neurotrophic-factor polymorphism and short-term antidepressant response in major depressive disorders","author":"Lin","year":"2008","journal-title":"Pharmgenomics Pers Med"},{"key":"key-10.4103\/0253-7613.215729-18","first-page":"1169","volume-title":"A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression","author":"Brunoni","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"key-10.4103\/0253-7613.215729-19","first-page":"56","volume-title":"A rating scale for depression","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-20","first-page":"3","volume-title":"The responsiveness of the Hamilton Depression Rating Scale","author":"Faries","year":"2000","journal-title":"J Psychiatr Res"},{"key":"key-10.4103\/0253-7613.215729-21","first-page":"261","volume-title":"The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: A preliminary study","author":"Aydemir","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-22","first-page":"281","volume-title":"Effects of fluoxetine and venlafaxine on serum brain derived neurotrophic factor levels in depressed patients","author":"Ba\u015fterzi","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-23","first-page":"66","volume-title":"Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment","author":"Hellweg","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"key-10.4103\/0253-7613.215729-24","first-page":"194","volume-title":"Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants","author":"Lee","year":"2008","journal-title":"Neuropsychobiology"},{"key":"key-10.4103\/0253-7613.215729-25","first-page":"247","volume-title":"Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine","author":"Matrisciano","year":"2009","journal-title":"J Psychiatr Res"},{"key":"key-10.4103\/0253-7613.215729-26","first-page":"1034","volume-title":"Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients","author":"Yoshimura","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key-10.4103\/0253-7613.215729-27","first-page":"183","volume-title":"Antidepressants and neuroplasticity","author":"D'Sa","year":"2002","journal-title":"Bipolar Disord"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:32:20Z","timestamp":1786714340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.IJP_700_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["215729"],"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_700_16","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}